Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON6 trial of cediranib for relapsed platinum-sensitive ovarian cancer
ISRCTN68510403Phase 3Completed
- Sponsor
- Medical Research Council
- Start
- Nov 2007
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of cediranib in ovarian cancer, fallopian tube cancer (PFTC) and serous peritoneal carcinoma (PPSC) (3 arms), sponsored by Medical Research Council. Primary endpoint: Progression-free survival in arms A versus C. Started Nov 2007; status: completed.
02
Drugs
cediranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)serous peritoneal carcinoma (PPSC)
Beyond the preview
Go deeper on ISRCTN68510403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN68510403.